Strides Pharma Science Limited announced that its step-down subsidiary, Strides Pharma International AG (SPIAG), has entered into definitive agreements with Sandoz AG and its group entities for the acquisition and in-licensing of a portfolio of branded generic products across Sub-Saharan Africa (SSA).

The agreement spans Western Sahara (covering 10 countries), Ghana, Nigeria, and Kenya. The portfolio includes branded generics across anti-infective, cardiovascular, and dermatology segments, with several products individually generating annual sales exceeding US$1 million.

The transaction includes a mix of products that are being fully acquired by Strides, as well as select products that Strides will continue to market on behalf of Sandoz. As part of the agreement, Strides will enter into a manufacturing and supply arrangement with Sandoz for continued production and supply.

With the combined portfolio, Strides is expected to be positioned among the top five pharmaceutical companies in the SSA region by sales, and among the top two in the representable market. The transaction is also expected to more than double Strides’ presence in the region.

The initial consideration for the transaction is US$12 million, payable at closing and expected to be funded through internal accruals. The transaction is expected to be EPS-accretive.

The transaction is expected to close by the end of Q2 FY27 (quarter ending September 2026), subject to regulatory and antitrust approvals.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!